AI assistant
ARIX BIOSCIENCE PLC Director's Dealing 2020
4968_dirs_2020-04-17_b301c6d5-ce93-4e8a-a7d1-4c78d217c1d9.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
Arix Bioscience Plc - Director/PDMR Shareholding
PR Newswire
London, April 17
17 April 2020
ARIX BIOSCIENCE PLC
Director/PDMR Shareholding
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Robert Lyne | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Operating Officer | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £0.8600 | 23,255 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 16 April 2020 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Marcus Karia | |
| 2 | Reason for the notification | ||
| a) | Position / status | Group Finance Director | |
| b) | Initial notification / Amendment |
Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £0.8617 | 11,604 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 16 April 2020 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
For further information:
Robert Lyne Chief Operating Officer and General Counsel +44 (0)207 290 1050
- Ends -
